Latest Insider Transactions at Homology Medicines, Inc. (FIXX)
This section provides a real-time view of insider transactions for Homology Medicines, Inc. (FIXX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Homology Medicines, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Homology Medicines, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2021
|
Timothy P Kelly Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+41.67%
|
$16,000
$4.76 P/Share
|
|
Jan 12
2021
|
Timothy P Kelly Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
500
-100.0%
|
$6,500
$13.0 P/Share
|
|
Jan 12
2021
|
Timothy P Kelly Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+50.0%
|
$3,000
$6.63 P/Share
|
|
Jan 07
2021
|
Albert Seymour |
SELL
Open market or private sale
|
Direct |
5,103
-3.8%
|
$61,236
$12.05 P/Share
|
|
Jan 06
2021
|
Albert Seymour |
SELL
Open market or private sale
|
Direct |
9,897
-6.87%
|
$118,764
$12.06 P/Share
|
|
Jan 05
2021
|
Albert Seymour |
SELL
Open market or private sale
|
Direct |
10,000
-6.49%
|
$110,000
$11.44 P/Share
|
|
Jan 04
2021
|
Timothy P Kelly Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,000
-100.0%
|
$44,000
$11.5 P/Share
|
|
Jan 04
2021
|
Timothy P Kelly Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+41.67%
|
$16,000
$4.76 P/Share
|
|
Dec 22
2020
|
5 Am Ventures Iv, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-9.93%
|
$6,000,000
$12.82 P/Share
|
|
Dec 22
2020
|
Kush Parmar Director |
SELL
Open market or private sale
|
Indirect |
500,000
-9.93%
|
$6,000,000
$12.82 P/Share
|
|
Dec 14
2020
|
5 Am Ventures Iv, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-4.61%
|
$6,000,000
$12.47 P/Share
|
|
Dec 14
2020
|
Kush Parmar Director |
SELL
Open market or private sale
|
Indirect |
500,000
-4.61%
|
$6,000,000
$12.47 P/Share
|
|
Jan 30
2020
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
509,970
-100.0%
|
$7,649,550
$15.45 P/Share
|
|
Jan 29
2020
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,857
-1.71%
|
$132,855
$15.45 P/Share
|
|
Jan 28
2020
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
65,891
-11.27%
|
$988,365
$15.51 P/Share
|
|
Jan 27
2020
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
193,359
-24.85%
|
$2,900,385
$15.77 P/Share
|
|
Jan 24
2020
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
380,256
-32.83%
|
$5,703,840
$15.69 P/Share
|
|
Dec 24
2019
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
350,000
-7.89%
|
$7,350,000
$21.95 P/Share
|
|
Dec 23
2019
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
130,979
-2.87%
|
$2,750,559
$21.83 P/Share
|
|
Dec 20
2019
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
21,129
-0.46%
|
$443,709
$21.5 P/Share
|
|
Dec 19
2019
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,622
-0.27%
|
$265,062
$21.68 P/Share
|
|
Apr 12
2019
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
533,333
+31.53%
|
$11,733,326
$22.5 P/Share
|
|
Apr 02
2018
|
Temasek Holdings (Private) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
625,000
+16.25%
|
$10,000,000
$16.0 P/Share
|
|
Apr 02
2018
|
Temasek Holdings (Private) LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,595,293
+38.8%
|
-
|
|
Apr 02
2018
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+34.65%
|
$20,000,000
$16.0 P/Share
|
|
Apr 02
2018
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,977,035
+44.94%
|
-
|
|
Apr 02
2018
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+27.91%
|
$4,000,000
$16.0 P/Share
|
|
Apr 02
2018
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
395,845
+50.0%
|
-
|
|
Apr 02
2018
|
Novartis Institutes For Bio Medical Research, Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,979,226
+50.0%
|
-
|